Treatment type
Treatments and trials using Injection, with the same country and access zoom as New Developments.
All New Developments
Mounjaro (tirzepatide) — weekly shot for adults with type 2 diabetes that now also carries a labelled heart-protection use
FDA supplemental approval effective 27 August 2026 for a new use of Mounjaro (tirzepatide) injection — a once-weekly subcutaneous dual…
This is for adults with type 2 diabetes who are at high risk for heart attack, stroke, or cardiovascular…
Trutakna (atacicept-vymj) — weekly under-the-skin shot to lower protein in the urine in adults with primary IgA nephropathy
FDA accelerated approval on 7 July 2026 for Trutakna (atacicept-vymj) injection — a weekly subcutaneous medicine — to reduce proteinuria in…
This is for adults with primary IgA nephropathy who leak protein into the urine and may be candidates for…
Lytenava (bevacizumab-vikg) — ophthalmic VEGF inhibitor injection for wet age-related macular degeneration
FDA approval on 24 July 2026 for Lytenava (bevacizumab-vikg) injection — an ophthalmic VEGF inhibitor for intravitreal use — for neovascular…
This is for adults with wet age-related macular degeneration who may be candidates for labelled US Lytenava…
Zycubo (copper histidinate) — subcutaneous copper replacement for Menkes disease in pediatric patients
FDA approval on 12 January 2026 for Zycubo (copper histidinate) for injection — a subcutaneous copper replacement — for Menkes disease in…
This is for families of children with Menkes disease who may be candidates for labelled US Zycubo…
Imaavy (nipocalimab-aahu) — neonatal Fc receptor blocker for warm autoimmune hemolytic anemia in adults and adolescents 12 years and older after corticosteroid exposure
FDA approval on 25 August 2026 for Imaavy (nipocalimab-aahu) injection — a neonatal Fc receptor (FcRn) blocker — for warm autoimmune hemolytic…
This is for people 12 years and older with warm autoimmune hemolytic anemia who are currently on or have…
Yuviwel (navepegritide) — once-weekly CNP analog for children ≥2 with achondroplasia
FDA accelerated approval on 27 February 2026 for Yuviwel (navepegritide) for injection — a C-type natriuretic peptide (CNP) analog / TransCon CNP…
This is for families of children aged 2 years and older with achondroplasia and open growth plates who may be…
Awiqli (insulin icodec / insulin icodec-abae) — once-weekly basal insulin
The first labelled once-weekly basal insulin. The United States (FDA, 26 Mar 2026) labels it only for adults with type 2 diabetes as an adjunct to diet…
The first labelled once-weekly basal insulin. The United States (FDA, 26 Mar 2026) labels it only for…
Zanvastro (zilganersen) for Alexander disease (AxD)
The first FDA-labelled medicine for Alexander disease — an ultra-rare, progressive GFAP leukodystrophy. On 3 September 2026 the FDA approved Zanvastro…
The first FDA-labelled medicine for Alexander disease — an ultra-rare, progressive GFAP leukodystrophy. On…
Hepcludex (bulevirtide) for chronic hepatitis D (HDV)
The first labelled drug for chronic hepatitis D. The United States (FDA accelerated, 22 May 2026) labels 8.5 mg subcutaneously once daily for adults…
The first labelled drug for chronic hepatitis D. The United States (FDA accelerated, 22 May 2026) labels…
Exdensur (depemokimab) for severe eosinophilic asthma — and, outside the United States, for nasal polyps
The FDA, Health Canada, the UK MHRA, Japan’s MHLW, the EU Commission, and (on the Australian PI) the TGA have labelled a twice-yearly anti-IL-5 injection. The…
The FDA, Health Canada, the UK MHRA, Japan’s MHLW, the EU Commission, and (on the Australian PI) the TGA have…
Mimrylo (rusfertide) for erythrocytosis in adults with polycythemia vera (PV)
The FDA labelled a once-weekly subcutaneous hepcidin mimetic for adults with polycythemia vera who still need frequent phlebotomies despite standard care.…
The FDA labelled a once-weekly subcutaneous hepcidin mimetic for adults with polycythemia vera who still need…
Fasenra (benralizumab) for hypereosinophilic syndrome
Health Canada and the FDA have labelled Fasenra for hypereosinophilic syndrome. Japan and Switzerland have too. The UK SmPC already carries the wording. The EU…
Health Canada and the FDA have labelled Fasenra for hypereosinophilic syndrome. Japan and Switzerland have…